A 61-year-old woman was diagnosed with a low-absorption tumor measuring 17×5.5×9 cm with fat density between the stomach and transverse colon by follow-up contrast-enhanced CT after surgery for early rectal cancer. The right gastroepiploic artery and vein flowed into the tumor. The tumor demonstrated high signal intensity on contrast-enhanced T2- weighted MRI images, while the overall signal intensity being suppressed on fat-suppressed T2-weighted images. Thus, the patient was diagnosed with primary omental liposarcoma and underwent surgery. The tumor, mainly located on the right omental wall with the right gastroepiploic artery and vein as feeding vessels, was hanging caudally from the greater omentum to the anterior and posterior lobes of the transverse colon. Due to the absence of peritoneal dissemination and infiltration into the surrounding organs, the transverse mesocolon was hollowed out and the entire tumor excised. Based on the histopathological findings, the patient was diagnosed with well-differentiated liposarcoma. Surgical resection is the first-line treatment for liposarcoma, and postoperative adjuvant chemotherapy is ineffective. Since the tumor was completely resected, the patient has survived without recurrence for 2 years and 6 months after surgery.
Download full-text PDF |
Source |
---|
CRSLS
January 2025
Department of Surgery, King Khalid University Hospital, Riyadh, Saudi Arabia.
Background: Obesity is an alarmingly increasing global public health issue. Laparoscopic sleeve gastrectomy (LSG) is the most common bariatric surgery owing to its simplicity, effectiveness, and low complication rates. The complications can be classified as early or late, with fistula formation being one of the most severe complications.
View Article and Find Full Text PDFJPRAS Open
March 2025
Department of Plastic & Reconstructive Surgery, Hospital Universitario Son Espases, Palma de Mallorca, Balearic Islands, Spain.
Introduction: Extensive scalp defects present a significant reconstructive challenge due to the complex needs of patients that are often beyond the scope of conventional therapies, which makes free flaps the most reliable solution. Despite the variety of free flaps available for such cases, there is a lack of clear criteria for selecting the most suitable option. The primary objective of this study was to provide a simplified guide for the selection of donor sites for free flaps for achieving optimal reconstruction outcomes.
View Article and Find Full Text PDFCancer Immunol Immunother
January 2025
Division of Oncology, Department of Clinical Sciences Lund, and Lund University Cancer Center, Lund University, Lund, Sweden.
Tertiary lymphoid structures (TLS) in the tumor microenvironment are prognostically beneficial in many solid cancer types. Reports on TLS in high-grade serous tubo-ovarian carcinoma (HGSC) are few, and the prognostic impact is unclear. We investigated mature TLS (mTLS), immature TLS (iTLS) and lymphoid aggregates (LA) in primary adnexal tumors (PTs) and synchronous omental/peritoneal metastases (pMets) of HGSC.
View Article and Find Full Text PDFCureus
December 2024
Cardiovascular Surgery, Sapporo Medical University, Sapporo, JPN.
An a (AEF) is a rare but life-threatening condition where an abnormal connection forms between the aorta and the gastrointestinal tract, most commonly the duodenum. It can be primary (arising spontaneously due to an aortic aneurysm or infection) or secondary (complicating prior vascular surgery). Immediate recognition and surgical intervention are critical to manage severe gastrointestinal bleeding and prevent fatal outcomes.
View Article and Find Full Text PDFCancer Med
January 2025
Gynaecological Cancer Research Group, Lowy Cancer Research Centre, School of Clinical Medicine, Faculty of Medicine & Health, University of New South Wales, Sydney, New South Wales, Australia.
Objective: Endometrial cancer is one of the few cancers for which mortality is still increasing. A lack of treatment options remains a major challenge, particularly for some subtypes of the disease. GZD824, also known as olverembatinib, is a multi-kinase inhibitor previously investigated in clinical trials for chronic myeloid leukaemia and Ph+ acute lymphoblastic leukaemia as a BCR-ABL inhibitor.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!